Cipla
Vijayasarathi Ramaswami is an accomplished pharmaceutical professional with extensive experience in quality management across multiple organizations. Currently serving as Joint President and Head of Global Quality at Cipla since May 2018, Vijayasarathi has previously held senior roles including Vice President of Formulations Corporate Quality at Glenmark Pharmaceuticals and Senior Director at Dr. Reddy's Laboratories, overseeing Global API Quality and Site Head for an API factory in Mexico. With a solid educational foundation in Pharmacy and Chemistry from the Birla Institute of Technology and Science and a postgraduate degree in General Management from the Indian Institute of Management, Vijayasarathi possesses a comprehensive skill set in formulations operations and quality assurance, contributing to advancements in pharmaceutical practices.
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.